Southern California's
Tech
Startup Directory
Showcasing Southern California's innovation, one startup at a time. Every funded and bootstrapped company, from seed round to first dollar of revenue, tracked as it happens.
Includes SEC Form D filings from the last 3 years, plus all-time totals for companies sourced from YC and news coverage.
Artificial Intelligence
The region's largest single cluster by company count — AI and machine learning threaded through nearly every other industry here, from defense to biotech to entertainment.
Aerospace & Defense
Home to SpaceX, Northrop Grumman, and a new wave of hypersonics and space-infrastructure startups.
Entertainment & Gaming Tech
Hollywood's production infrastructure, live events, and a growing games and creator-tools scene.
Semiconductor Hardware
Qualcomm and Broadcom anchor a chip-design cluster spanning the region.
Medical Technology
A deep biotech research base and a growing bench of medical device and diagnostics startups.
B2B
Business software and services sold to other companies. The largest single category of startup across Southern California, spanning sales tools, vertical operating systems, and everything in between.
Industrials
Manufacturing, hardware, and physical-world operations. Overlaps heavily with the region's decades-old aerospace and defense manufacturing base, now extending into robotics and automated production.
Consumer
Products and apps built directly for individual consumers, drawing on Southern California's media and entertainment base.
Healthcare
Health tech, medical devices, and healthcare services, backed by a decades-old biotech research base and a deep bench of clinical and diagnostics startups.
Fintech
Financial technology: payments, banking, investing, and financial infrastructure.
Education
Education technology and learning platforms built across Southern California.
Real Estate & Construction
Property technology, construction tech, and real estate services.
Series F$225.9M
Series B$212.1MScience Seralutinib Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
$206.2MFounded by Ken Song and launched with over $370 million (later exceeding $500 million) from investors including Venrock Healthcare Capital Partners, RA Capital Management, and Fairmount.
$200.0MAnchored by our protein-engineering expertise and our proprietary single-domain antibody platform, we’ve developed a unique pipeline of therapeutic candidates.
Series C$200.0MHas raised over $350 million from major healthcare investors including OrbiMed, BlackRock, and Bain Capital Life Sciences.
Series B$200.0MCo-founded by CEO Todd Harris and COO Daniel Bensen, and was incubated by venture firm Alta Partners before going public.
Series D$195.7MABA therapy and comprehensive autism care for children, from diagnosis through developmental and medical therapy. Physician-led and in-network. Find a center near you.
Series B$172.8MWe are on a mission to exponentially improve the number of quality years for patients.